Spyre Therapeutics, Inc. (SYRE) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
SYRE Revenue Growth
Revenue Breakdown (FY 2023)
SYRE's revenue distribution by segment and geography for fiscal year 2023
By Product/Segment
SYRE Revenue Analysis (2014–2025)
As of May 8, 2026, Spyre Therapeutics, Inc. (SYRE) generated trailing twelve-month (TTM) revenue of $90.5 million. The most recent quarter (Q1 2026) recorded $0 in revenue, down 100.0% sequentially.
Looking at the longer-term picture, SYRE's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $18.7 million in 2021.
Revenue diversification analysis shows SYRE's business is primarily driven by License (0%).
When compared to Healthcare sector peers including ARRY (+13.2% YoY), PRTA (-58.0% YoY), and TRMB (+3.2% YoY). Compare SYRE vs ARRY →
SYRE Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| SYRECurrent | $90M | - | - | - | |
 ARRY | $1.3B | +13.2% | +8.0% | 6.6% | |
 PRTA | $10M | -58.0% | +62.6% | -1905.8% | |
 TRMB | $3.6B | +3.2% | +2.6% | 16.9% | |
 PTGX | $46M | -91.5% | +10.0% | -343.6% |
SYRE Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | - | $-171,653,000 | - | $-209,562,000 | - |
| 2024 | $0 | -100.0% | $0 | - | $-208,566,000 | - |
| 2023 | $886K | -62.0% | $886K | 100.0% | $-242,303,000 | -27348.0% |
| 2022 | $2.3M | -87.6% | $2.3M | 100.0% | $-84,781,000 | -3640.2% |
| 2021 | $18.7M | - | $18.7M | 100.0% | $-65,649,000 | -350.3% |
| 2020 | $0 | - | $-1,624,000 | - | $-81,481,000 | - |
| 2019 | $0 | -100.0% | $-901,000 | - | $-80,334,000 | - |
| 2018 | $3.9M | -25.3% | $0 | - | $-45,463,000 | -1169.3% |
| 2017 | $5.2M | +12.5% | $0 | - | $-27,676,000 | -531.7% |
| 2016 | $4.6M | -23.9% | $0 | - | $-21,906,000 | -473.3% |
Full SYRE Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See SYRE's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SYRE Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SYRE vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonSYRE — Frequently Asked Questions
Quick answers to the most common questions about buying SYRE stock.
Is SYRE's revenue growth accelerating or slowing?
SYRE TTM revenue: $90M. YoY growth: N/A. 5-year CAGR: N/A.
What is SYRE's long-term revenue growth rate?
Spyre Therapeutics, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is SYRE's revenue distributed by segment?
SYRE reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.